Pharmaust Ltd
ASX:PAA

Watchlist Manager
Pharmaust Ltd Logo
Pharmaust Ltd
ASX:PAA
Watchlist
Price: 0.165 AUD -8.33% Market Closed
Market Cap: 81.2m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

PAA doesn't have a meaningful market cap.

The Relative Value of one PAA stock under the Base Case scenario is 0.009 AUD. Compared to the current market price of 0.165 AUD, Pharmaust Ltd is Overvalued by 95%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PAA Relative Value
Base Case
0.009 AUD
Overvaluation 95%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

93.7
P/S
P/S
Price to Sales
93.7
vs History
11
vs Industry
3
Median 3Y
57
Median 5Y
15
Industry
2.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-12.2
Median 5Y
-23.3
Industry
22.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-23.6
Median 5Y
-36.9
Industry
17.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-20
Median 5Y
-30.8
Industry
23.3
More Details
7.9
P/B
P/B
Price to Book Value
7.9
vs History
20
vs Industry
8
Median 3Y
7.9
Median 5Y
5.8
Industry
2.3
More Details
82.5
EV/S
EV/S
Enterprise Value to Sales
82.5
vs History
11
vs Industry
3
Median 3Y
56.4
Median 5Y
14.3
Industry
2.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
6
Median 3Y
0
Median 5Y
9.2
Industry
5.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-21.9
Median 5Y
-26.9
Industry
13.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-21.9
Median 5Y
-26.9
Industry
16.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-22.9
Median 5Y
-36.1
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-22.4
Median 5Y
-32.1
Industry
17.6
More Details
122.4
EV/IC
EV/IC
Enterprise Value to IC
122.4
vs History
9
vs Industry
1
Median 3Y
14.7
Median 5Y
6.5
Industry
2
More Details

Multiples Across Competitors

PAA Competitors Multiples
Pharmaust Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Pharmaust Ltd
ASX:PAA
81.2m AUD 93.7 -10.6 -12.3 -12.3
US
Eli Lilly and Co
NYSE:LLY
712B USD 13.4 51.6 30.5 33.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
423.8B USD 4.7 18.7 14.2 18.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 15.5 11.3 12.6
CH
Roche Holding AG
SIX:ROG
210.9B CHF 3.5 25.5 9.6 11.2
CH
Novartis AG
SIX:NOVN
189.3B CHF 4.3 17.4 10.5 13.9
UK
AstraZeneca PLC
LSE:AZN
175.3B GBP 4.2 28.5 112.9 168.8
US
Merck & Co Inc
NYSE:MRK
205.1B USD 3.2 12.5 8.1 9.6
IE
Endo International PLC
LSE:0Y5F
197.4B USD 85.1 -67.5 313.3 785.7
US
Pfizer Inc
NYSE:PFE
136.6B USD 2.1 12.7 7.2 9.9
P/E Multiple
Earnings Growth PEG
AU
Pharmaust Ltd
ASX:PAA
Average P/E: 22.8
Negative Multiple: -10.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.6
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.7
28%
0.7
DK
Novo Nordisk A/S
CSE:NOVO B
15.5
10%
1.6
CH
Roche Holding AG
SIX:ROG
25.5
29%
0.9
CH
Novartis AG
SIX:NOVN
17.4
18%
1
UK
AstraZeneca PLC
LSE:AZN
28.5
37%
0.8
US
Merck & Co Inc
NYSE:MRK
12.5
16%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -67.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
12.7
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Pharmaust Ltd
ASX:PAA
Average EV/EBITDA: 436.4
Negative Multiple: -12.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.5
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.2
8%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
13%
0.9
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
112.9
10%
11.3
US
Merck & Co Inc
NYSE:MRK
8.1
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
313.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Pharmaust Ltd
ASX:PAA
Average EV/EBIT: 1 876.6
Negative Multiple: -12.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.1
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.7
14%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
7%
1.8
CH
Roche Holding AG
SIX:ROG
11.2
5%
2.2
CH
Novartis AG
SIX:NOVN
13.9
11%
1.3
UK
AstraZeneca PLC
LSE:AZN
168.8
22%
7.7
US
Merck & Co Inc
NYSE:MRK
9.6
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
785.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
9.9
10%
1

See Also

Summary
PAA intrinsic value, competitors valuation, and company profile.
DCF Valuation
PAA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PAA stock valuation using valuation multiples.
Wall Street Estimates
PAA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PAA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 283,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.